Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Cited by (363)

Items 101–200 of 363

1. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
   Maddox, Thomas M., Januzzi, James L., Allen, Larry A., Breathett, Khadijah, Brouse, Sara, Butler, Javed, Davis, Leslie L., Fonarow, Gregg C., Ibrahim, Nasrien E., Lindenfeld, JoAnn et al. · 2024 · Journal of the American College of Cardiology
2. When and how can real world data analyses substitute for randomized controlled trials?
   Franklin, Jessica M., Schneeweiss, Sebastian · 2017 · Clinical Pharmacology & Therapeutics
3. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
   Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Cefalu, William T., Januzzi, James L., Kalyani, Rita Rastogi, Kosiborod, Mikhail, Magwire, Melissa L., Morris, Pamela B. et al. · 2018 · Journal of the American College of Cardiology
4. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
   Tentolouris, Anastasios, Vlachakis, Panayotis, Tzeravini, Evangelia, Eleftheriadou, Ioanna, Tentolouris, Nikolaos · 2019 · International Journal of Environmental Research and Public Health
5. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
   Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo et al. · 2021 · Circulation
6. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
   Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
7. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
   Yun, Jae-Seung, Ko, Seung-Hyun · 2021 · Metabolism
8. Nocturnal Hypertension: New Technology and Evidence
   Kario, Kazuomi · 2018 · Hypertension
9. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
   Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
10. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
    Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., Mehta, R., Woo, V., Lingvay, I. · 2019 · Diabetes & Metabolism
11. 11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
    American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
12. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
    Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George et al. · 2019 · Circulation
13. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
    de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A. et al. · 2020 · Kidney International
14. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging
    Kidokoro, Kengo, Cherney, David Z.I., Bozovic, Andrea, Nagasu, Hajime, Satoh, Minoru, Kanda, Eiichiro, Sasaki, Tamaki, Kashihara, Naoki · 2019 · Circulation
15. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
    Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K. et al. · 2024 · Journal of the American College of Cardiology
16. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
    Blau, Jenny E., Tella, Sri Harsha, Taylor, Simeon I., Rother, Kristina I. · 2017 · Diabetes/Metabolism Research and Reviews
17. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity
    Packer, Milton · 2018 · Circulation
18. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
    Ludvik, Bernhard, Frías, Juan P, Tinahones, Francisco J, Wainstein, Julio, Jiang, Honghua, Robertson, Kenneth E, García-Pérez, Luis-Emilio, Woodward, D Bradley, Milicevic, Zvonko · 2018 · The Lancet Diabetes &amp; Endocrinology
19. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
    Dekkers, Claire C. J., Petrykiv, Sergei, Laverman, Gozewijn D., Cherney, David Z., Gansevoort, Ron T., Heerspink, Hiddo J. L. · 2018 · Diabetes, Obesity and Metabolism
20. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
21. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
    Nauck, Michael A, Meier, Juris J · 2019 · European Journal of Endocrinology
22. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
23. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
    Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei et al. · 2018 · Circulation
24. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
    Shaman, Ahmed M., Bain, Stephen C., Bakris, George L., Buse, John B., Idorn, Thomas, Mahaffey, Kenneth W., Mann, Johannes F.E., Nauck, Michael A., Rasmussen, Søren, Rossing, Peter et al. · 2022 · Circulation
25. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
    Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay et al. · 2021 · The Lancet Diabetes &amp; Endocrinology
26. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
    Mancini, Sarah J., Boyd, Daria, Katwan, Omar J., Strembitska, Anastasiya, Almabrouk, Tarek A., Kennedy, Simon, Palmer, Timothy M., Salt, Ian P. · 2018 · Scientific Reports
27. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
    Cosentino, Francesco, Cannon, Christopher P., Cherney, David Z.I., Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J. et al. · 2020 · Circulation
28. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics
    Jardine, Meg J., Mahaffey, Kenneth W., Neal, Bruce, Agarwal, Rajiv, Bakris, George L., Brenner, Barry M., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick et al. · 2017 · American Journal of Nephrology
29. SGLT2 Inhibitor–Induced Sympathoinhibition
    Herat, Lakshini Y., Magno, Aaron L., Rudnicka, Caroline, Hricova, Jana, Carnagarin, Revathy, Ward, Natalie C., Arcambal, Angelique, Kiuchi, Marcio G., Head, Geoff A., Schlaich, Markus P. et al. · 2020 · JACC: Basic to Translational Science
30. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
    Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin et al. · 2018 · Clinical Kidney Journal
31. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
    Zelniker, Thomas A., Braunwald, Eugene · 2018 · Journal of the American College of Cardiology
32. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies
    Silbert, Richard, Salcido-Montenegro, Alejandro, Rodriguez-Gutierrez, Rene, Katabi, Abdulrahman, McCoy, Rozalina G. · 2018 · Current Diabetes Reports
33. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus
    Halden, Thea Anine Strøm, Kvitne, Kine Eide, Midtvedt, Karsten, Rajakumar, Laavanyaah, Robertsen, Ida, Brox, Jan, Bollerslev, Jens, Hartmann, Anders, Åsberg, Anders, Jenssen, Trond · 2019 · Diabetes Care
34. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
    Marjot, Thomas, Moolla, Ahmad, Cobbold, Jeremy F, Hodson, Leanne, Tomlinson, Jeremy W · 2020 · Endocrine Reviews
35. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
    DeFronzo, Ralph A, Inzucchi, Silvio, Abdul-Ghani, Muhammad, Nissen, Steven E · 2019 · Diabetes and Vascular Disease Research
36. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
    Donnan, Jennifer R, Grandy, Catherine A, Chibrikov, Eugene, Marra, Carlo A, Aubrey-Bassler, Kris, Johnston, Karissa, Swab, Michelle, Hache, Jenna, Curnew, Daniel, Nguyen, Hai et al. · 2019 · BMJ Open
37. The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics
    McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S. et al. · 2019 · European Journal of Heart Failure
38. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study
    Patorno, Elisabetta, Pawar, Ajinkya, Franklin, Jessica M., Najafzadeh, Mehdi, Déruaz-Luyet, Anouk, Brodovicz, Kimberly G., Sambevski, Steven, Bessette, Lily G., Santiago Ortiz, Adrian J., Kulldorff, Martin et al. · 2019 · Circulation
39. Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( <scp>CVD‐REAL Nordic</scp> ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: <scp>A</scp> multinational observational study
    Persson, Frederik, Nyström, Thomas, Jørgensen, Marit E., Carstensen, Bendix, Gulseth, Hanne L., Thuresson, Marcus, Fenici, Peter, Nathanson, David, Eriksson, Jan W., Norhammar, Anna et al. · 2018 · Diabetes, Obesity and Metabolism
40. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
    Abraham, William T, Lindenfeld, JoAnn, Ponikowski, Piotr, Agostoni, Piergiuseppe, Butler, Javed, Desai, Akshay S, Filippatos, Gerasimos, Gniot, Jacek, Fu, Michael, Gullestad, Lars et al. · 2021 · European Heart Journal
41. Glomerular hyperfiltration
    Cortinovis, Monica, Perico, Norberto, Ruggenenti, Piero, Remuzzi, Andrea, Remuzzi, Giuseppe · 2022 · Nature Reviews Nephrology
42. 13. Older Adults: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
43. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
    Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina · 2020 · Diabetes, Obesity and Metabolism
44. A role for tubular Na⁺/H⁺exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
    Onishi, Akira, Fu, Yiling, Patel, Rohit, Darshi, Manjula, Crespo-Masip, Maria, Huang, Winnie, Song, Panai, Freeman, Brent, Kim, Young Chul, Soleimani, Manoocher et al. · 2020 · American Journal of Physiology-Renal Physiology
45. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
    Pollock, Carol, Stefánsson, Bergur, Reyner, Daniel, Rossing, Peter, Sjöström, C David, Wheeler, David C, Langkilde, Anna Maria, Heerspink, Hiddo J L · 2019 · The Lancet Diabetes &amp; Endocrinology
46. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
    Cusi, Kenneth, Bril, Fernando, Barb, Diana, Polidori, David, Sha, Sue, Ghosh, Atalanta, Farrell, Kristin, Sunny, Nishanth E., Kalavalapalli, Srilaxmi, Pettus, Jeremy et al. · 2019 · Diabetes, Obesity and Metabolism
47. Effects of dapagliflozin in stage 4 chronic kidney disease
    Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David et al. · 2021 · Journal of the American Society of Nephrology
48. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study
    Fioretto, Paola, Del Prato, Stefano, Buse, John B., Goldenberg, Ronald, Giorgino, Francesco, Reyner, Daniel, Langkilde, Anna Maria, Sjöström, C. David, Sartipy, Peter, On Behalf of the DERIVE Study Investigators · 2018 · Diabetes, Obesity and Metabolism
49. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
    Rangaswami, Janani, Bhalla, Vivek, de Boer, Ian H., Staruschenko, Alexander, Sharp, Johanna A., Singh, Radhika Rajgopal, Lo, Kevin Bryan, Tuttle, Katherine, Vaduganathan, Muthiah, Ventura, Hector et al. · 2020 · Circulation
50. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
    Sano, Motoaki · 2018 · Journal of Cardiology
51. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
    Lee, P. C., Ganguly, S., Goh, S.‐Y. · 2018 · Obesity Reviews
52. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
    Nadkarni, Girish N., Ferrandino, Rocco, Chang, Alexander, Surapaneni, Aditya, Chauhan, Kinsuk, Poojary, Priti, Saha, Aparna, Ferket, Bart, Grams, Morgan E., Coca, Steven G. · 2017 · Diabetes Care
53. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial
    Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea et al. · 2020 · Diabetes Care
54. Anti-diabetic drugs and weight loss in patients with type 2 diabetes
    Lazzaroni, Elisa, Ben Nasr, Moufida, Loretelli, Cristian, Pastore, Ida, Plebani, Laura, Lunati, Maria Elena, Vallone, Luciana, Bolla, Andrea Mario, Rossi, Antonio, Montefusco, Laura et al. · 2021 · Pharmacological Research
55. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis
    Cai, Xiaoling, Yang, Wenjia, Gao, Xueying, Chen, Yifei, Zhou, Lingli, Zhang, Simin, Han, Xueyao, Ji, Linong · 2018 · Obesity
56. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study
    Blau, Jenny E., Bauman, Viviana, Conway, Ellen M., Piaggi, Paolo, Walter, Mary F., Wright, Elizabeth C., Bernstein, Shanna, Courville, Amber B., Collins, Michael T., Rother, Kristina I. et al. · 2018 · JCI Insight
57. Obesity-Related Heart Failure With a Preserved Ejection Fraction
    Packer, Milton, Kitzman, Dalane W. · 2018 · JACC: Heart Failure
58. Sodium—Glucose cotransporter inhibitors and oxidative stress: An update
    Yaribeygi, Habib, Atkin, Stephen L., Butler, Alexandra E., Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
59. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
    Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Memon, Muhammad Mustafa, Khan, Muhammad Shahzeb, Rawasia, Wasiq Faraz, Talha Ayub, Muhammad, Sreenivasan, Jayakumar, Golzar, Yasmeen · 2018 · European Journal of Preventive Cardiology
60. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes
    Chang, Hsien-Yen, Singh, Sonal, Mansour, Omar, Baksh, Sheriza, Alexander, G. Caleb · 2018 · JAMA Internal Medicine
61. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics
    Liu, Zhenghong, Ma, Xiaoxuan, Ilyas, Iqra, Zheng, Xueying, Luo, Sihui, Little, Peter J., Kamato, Danielle, Sahebkar, Amirhossein, Wu, Weiming, Weng, Jianping et al. · 2021 · Theranostics
62. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
    Sen, Taha, Heerspink, Hiddo J.L. · 2021 · Cell Metabolism
63. 13. Older Adults: <i>Standards of Care in Diabetes—2024</i>
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L., Khunti, Kamlesh et al. · 2024 · Diabetes Care
64. Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association
    Creager, Mark A., Matsushita, Kunihiro, Arya, Shipra, Beckman, Joshua A., Duval, Sue, Goodney, Philip P., Gutierrez, J. Antonio T., Kaufman, John A., Joynt Maddox, Karen E., Pollak, Amy W. et al. · 2021 · Circulation
65. Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
    The GRADE Study Research Group · 2022 · New England Journal of Medicine
66. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
    Ghosh-Swaby, Olivia R, Goodman, Shaun G, Leiter, Lawrence A, Cheng, Alice, Connelly, Kim A, Fitchett, David, Jüni, Peter, Farkouh, Michael E, Udell, Jacob A · 2020 · The Lancet Diabetes &amp; Endocrinology
67. Benefits and harms of intensive glycemic control in patients with type 2 diabetes
    Rodriguez-Gutierrez, René, Gonzalez-Gonzalez, José Gerardo, Zuñiga-Hernandez, Jorge A, McCoy, Rozalina G · 2019 · BMJ
68. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
    Lipscombe, Lorraine, Butalia, Sonia, Dasgupta, Kaberi, Eurich, Dean T., MacCallum, Lori, Shah, Baiju R., Simpson, Scot, Senior, Peter A. · 2020 · Canadian Journal of Diabetes
69. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
    Mann, Johannes F. E., Fonseca, Vivian, Mosenzon, Ofri, Raz, Itamar, Goldman, Bryan, Idorn, Thomas, von Scholten, Bernt Johan, Poulter, Neil R., The LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2018 · Circulation
70. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
    Simms-Williams, Nikita, Treves, Nir, Yin, Hui, Lu, Sally, Yu, Oriana, Pradhan, Richeek, Renoux, Christel, Suissa, Samy, Azoulay, Laurent · 2024 · BMJ
71. Weight management in patients with type 1 diabetes and obesity
    Mottalib, Adham, Kasetty, Megan, Mar, Jessica Y., Elseaidy, Taha, Ashrafzadeh, Sahar, Hamdy, Osama · 2017 · Current Diabetes Reports
72. Diagnosis and Treatment of Type 2 Diabetes in Adults
    Kalyani, Rita R., Neumiller, Joshua J., Maruthur, Nisa M., Wexler, Deborah J. · 2025 · JAMA
73. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America
    Dunlay, Shannon M., Givertz, Michael M., Aguilar, David, Allen, Larry A., Chan, Michael, Desai, Akshay S., Deswal, Anita, Dickson, Victoria Vaughan, Kosiborod, Mikhail N., Lekavich, Carolyn L. et al. · 2019 · Journal of Cardiac Failure
74. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
    Li, JingWei, Woodward, Mark, Perkovic, Vlado, Figtree, Gemma A., Heerspink, Hiddo J.L., Mahaffey, Kenneth W., de Zeeuw, Dick, Vercruysse, Frank, Shaw, Wayne, Matthews, David R. et al. · 2020 · JACC: Heart Failure
75. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
    Karagiannis, Thomas, Tsapas, Apostolos, Athanasiadou, Eleni, Avgerinos, Ioannis, Liakos, Aris, Matthews, David R., Bekiari, Eleni · 2021 · Diabetes Research and Clinical Practice
76. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
    Puglisi, Soraya, Rossini, Alessandro, Poli, Roberta, Dughera, Francesca, Pia, Anna, Terzolo, Massimo, Reimondo, Giuseppe · 2021 · Frontiers in Endocrinology
77. Racial and Ethnic Disparities in Peripheral Artery Disease
    Hackler, Eddie L., Hamburg, Naomi M., White Solaru, Khendi T. · 2021 · Circulation Research
78. Long-Term Weight Loss Strategies for Obesity
    Kheniser, Karim, Saxon, David R, Kashyap, Sangeeta R · 2021 · The Journal of Clinical Endocrinology &amp; Metabolism
79. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
    Dhatariya, Ketan, Bain, Stephen C., Buse, John B., Simpson, Richard, Tarnow, Lise, Kaltoft, Margit Staum, Stellfeld, Michael, Tornøe, Karen, Pratley, Richard E., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2018 · Diabetes Care
80. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
    Khan, Muhammad Shahzeb, Fonarow, Gregg C., McGuire, Darren K., Hernandez, Adrian F., Vaduganathan, Muthiah, Rosenstock, Julio, Handelsman, Yehuda, Verma, Subodh, Anker, Stefan D., McMurray, John J.V. et al. · 2020 · Circulation
81. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism
    Layton, Anita T., Vallon, Volker · 2018 · American Journal of Physiology-Renal Physiology
82. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
    Mahtta, Dhruv, Ramsey, David J., Lee, Michelle T., Chen, Liang, Al Rifai, Mahmoud, Akeroyd, Julia M., Vaughan, Elizabeth M., Matheny, Michael E., Santo, Karla Rodrigues do Espirito, Navaneethan, Sankar D. et al. · 2022 · Diabetes Care
83. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
    Schwaiger, Elisabeth, Burghart, Lukas, Signorini, Lorenzo, Ristl, Robin, Kopecky, Chantal, Tura, Andrea, Pacini, Giovanni, Wrba, Thomas, Antlanger, Marlies, Schmaldienst, Sabine et al. · 2019 · American Journal of Transplantation
84. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
    Georgianos, Panagiotis I., Agarwal, Rajiv · 2019 · Diabetes Care
85. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
    Li, JingWei, Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Neuen, Brendon L., Arnott, Clare, Simpson, Roger, Oh, Richard, Mahaffey, Kenneth W., Heerspink, Hiddo J.L. · 2020 · Kidney International
86. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation
    Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K. et al. · 2021 · Diabetes
87. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus
    Woods, T. Cooper, Satou, Ryousuke, Miyata, Kayoko, Katsurada, Akemi, Dugas, Courtney M., Klingenberg, Natasha C., Fonseca, Vivian A., Navar, L. Gabriel · 2019 · American Journal of Nephrology
88. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial
    Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki, van Raalte, Daniël H., Heerspink, Hiddo J.L. · 2021 · Diabetes Care
89. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
    Taylor, Simeon I, Blau, Jenny E, Rother, Kristina I, Beitelshees, Amber L · 2019 · The Lancet Diabetes &amp; Endocrinology
90. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
    Scheen, André J. · 2019 · Current Cardiology Reports
91. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
    McCoy, Rozalina G., Dykhoff, Hayley J., Sangaralingham, Lindsey, Ross, Joseph S., Karaca-Mandic, Pinar, Montori, Victor M., Shah, Nilay D. · 2019 · Diabetes Technology &amp; Therapeutics
92. Personalized type 2 diabetes management: an update on recent advances and recommendations
    Williams, David M, Jones, Hannah, Stephens, Jeffrey W · 2022 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
93. Do sulphonylureas still have a place in clinical practice?
    Khunti, Kamlesh, Chatterjee, Sudesna, Gerstein, Hertzel C, Zoungas, Sophia, Davies, Melanie J · 2018 · The Lancet Diabetes &amp; Endocrinology
94. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial
    Bethel, M. Angelyn, Mentz, Robert J., Merrill, Peter, Buse, John B., Chan, Juliana C., Goodman, Shaun G., Iqbal, Nayyar, Jakuboniene, Neli, Katona, Brian, Lokhnygina, Yuliya et al. · 2020 · Diabetes Care
95. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure
    Marso, Steven P., Baeres, Florian M.M., Bain, Stephen C., Goldman, Bryan, Husain, Mansoor, Nauck, Michael A., Poulter, Neil R., Pratley, Richard E., Thomsen, Anne Bloch, Buse, John B. · 2020 · Journal of the American College of Cardiology
96. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
    Wan, Ningning, Rahman, Asadur, Hitomi, Hirofumi, Nishiyama, Akira · 2018 · Frontiers in Endocrinology
97. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
    Mechanick, Jeffrey I., Farkouh, Michael E., Newman, Jonathan D., Garvey, W. Timothy · 2020 · Journal of the American College of Cardiology
98. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
    Ye, Nan, Jardine, Meg J., Oshima, Megumi, Hockham, Carinna, Heerspink, Hiddo J.L., Agarwal, Rajiv, Bakris, George, Schutte, Aletta E., Arnott, Clare, Chang, Tara I. et al. · 2021 · Circulation
99. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
    Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J.L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A. et al. · 2021 · Diabetes Care
100. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
     Singh, Awadhesh Kumar, Singh, Ritu · 2020 · Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews